[go: up one dir, main page]

WO2005084636A3 - A process for the preparation of controlled-release pharmaceutical composition of metoprolol - Google Patents

A process for the preparation of controlled-release pharmaceutical composition of metoprolol Download PDF

Info

Publication number
WO2005084636A3
WO2005084636A3 PCT/IB2005/000501 IB2005000501W WO2005084636A3 WO 2005084636 A3 WO2005084636 A3 WO 2005084636A3 IB 2005000501 W IB2005000501 W IB 2005000501W WO 2005084636 A3 WO2005084636 A3 WO 2005084636A3
Authority
WO
WIPO (PCT)
Prior art keywords
metoprolol
release pharmaceutical
pharmaceutical composition
controlled
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/000501
Other languages
French (fr)
Other versions
WO2005084636A2 (en
Inventor
Rajeev Singh Raghuvanshi
Pramod Kharwade
Prashant Manohar Mandaogade
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2005084636A2 publication Critical patent/WO2005084636A2/en
Anticipated expiration legal-status Critical
Publication of WO2005084636A3 publication Critical patent/WO2005084636A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to processes for preparing an oral controlled-release pharmaceutical composition of metoprolol succinate comprising a plurality of beads, which comprise a water soluble or water swellable inert core. Further, the present invention relates to processes of preparing oral controlled-release pharmaceutical compositions of metoprolol succinate comprising a plurality of beads, which comprise an inert core and one or more drug layers comprising metoprolol, wherein the soluble component of inert core and one or more drug layers comprise less than 95% w/w of a salt of metoprolol.
PCT/IB2005/000501 2004-02-27 2005-02-25 A process for the preparation of controlled-release pharmaceutical composition of metoprolol Ceased WO2005084636A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN305/DEL/2004 2004-02-27
IN305DE2004 2004-02-27

Publications (2)

Publication Number Publication Date
WO2005084636A2 WO2005084636A2 (en) 2005-09-15
WO2005084636A3 true WO2005084636A3 (en) 2006-11-30

Family

ID=34917507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000501 Ceased WO2005084636A2 (en) 2004-02-27 2005-02-25 A process for the preparation of controlled-release pharmaceutical composition of metoprolol

Country Status (1)

Country Link
WO (1) WO2005084636A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005060393A1 (en) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Pharmaceutical pellet, useful for the production of tablet, comprises a spherical active agent, preferably metroprololsuccinate, comprising core with smooth surface and a coat on the core, where the active agent release is pH-independent
US20070202172A1 (en) * 2006-02-24 2007-08-30 Tomer Gold Metoprolol succinate E.R. tablets and methods for their preparation
EP2184056B1 (en) 2007-08-27 2019-04-24 Asahi Kasei Kabushiki Kaisha Process for production of tablets containing both crystalline cellulose and granules
RU2014127884A (en) * 2011-12-09 2016-02-10 Вокхардт Лимитед WAYS OF TREATMENT OF CARDIOVASCULAR DISORDER
CN102973515B (en) * 2012-11-28 2016-12-21 康普药业股份有限公司 One treats hypertension, anginal slow releasing preparation
CN104274387A (en) * 2013-07-03 2015-01-14 广东东阳光药业有限公司 Metoprolol Sustained Release Composition
IN2013MU03221A (en) * 2013-10-14 2015-07-03 Zim Lab Ltd
CN105193757A (en) * 2014-06-23 2015-12-30 中国人民解放军军事医学科学院毒物药物研究所 Metoprolol sustained-release composition and preparation method thereof
CN111419813A (en) * 2020-05-09 2020-07-17 深圳市道科思医药有限公司 Metoprolol succinate sustained-release tablet and preparation method thereof
WO2022074681A1 (en) * 2020-10-08 2022-04-14 Harman Finochem Limited Pharmaceutical compositions with enhanced blend uniformity and content uniformity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871549A (en) * 1985-07-19 1989-10-03 Fujisawa Pharmaceutical Co., Ltd. Time-controlled explosion systems and processes for preparing the same
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
WO2003051340A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab New film coating
US20030185887A1 (en) * 2002-03-28 2003-10-02 Chih-Ming Chen Controlled release oral dosage form of beta-adrenergic blocking agents
US20050008701A1 (en) * 2003-07-11 2005-01-13 Mongkol Sriwongjanva Formulation and process for drug loaded cores

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871549A (en) * 1985-07-19 1989-10-03 Fujisawa Pharmaceutical Co., Ltd. Time-controlled explosion systems and processes for preparing the same
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
WO2003051340A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab New film coating
US20030185887A1 (en) * 2002-03-28 2003-10-02 Chih-Ming Chen Controlled release oral dosage form of beta-adrenergic blocking agents
US20050008701A1 (en) * 2003-07-11 2005-01-13 Mongkol Sriwongjanva Formulation and process for drug loaded cores

Also Published As

Publication number Publication date
WO2005084636A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2011084593A3 (en) Abuse-resistant formulations
WO2008064202A3 (en) Modified-release formulations of calcium receptor-active compounds
IL172331A (en) Process for preparing an 8-halo-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine compound, an intermediate compound, method of resolving a mixture of the compounds, a salt of a stereoisomer of tartaric acid and the compound, a hydrochloric acid salt of the compound, a composition and use of a hydrochloric acid salt in the manufacture of a medicament
WO2006063841A3 (en) Trycyclic heterocycles, their manufacture and use as pharmaceutical agents
IL210756A0 (en) Carbostyril compound, process for their preparation and pharmaceutical compositions containing them
WO2005117843A3 (en) Sustained release preparations
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
IL193357A0 (en) Metoprolol succinate e.r. tablets and methods for their preparation
WO2005084636A3 (en) A process for the preparation of controlled-release pharmaceutical composition of metoprolol
EP2133140A3 (en) Fast-release microcapsule products
WO2006114520A3 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
WO2003026610A3 (en) Process for the preparation of fast dissolving dosage form
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
AU2003202719A1 (en) Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
WO2009019599A3 (en) Extended release compositions comprising tolterodine
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2008071966A3 (en) Pharmaceutical composition of zolpidem
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase